R R

What Is the Success Rate of Teprotumumab for Thyroid Eye Disease?

Teprotumumab, marketed as Tepezza, is the first FDA-approved biological therapy for Thyroid Eye Disease (TED). Unlike older treatments that only addressed inflammation, teprotumumab targets the underlying IGF-1 receptors that cause tissue expansion behind the eye. In 2026, it is recognized as a breakthrough for preventing the disfiguring "bulging" and double vision associated with Graves' Orbitopathy.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is the Success Rate of Teprotumumab for Thyroid Eye Disease?

Teprotumumab, marketed as Tepezza, is the first FDA-approved biological therapy for Thyroid Eye Disease (TED). Unlike older treatments that only addressed inflammation, teprotumumab targets the underlying IGF-1 receptors that cause tissue expansion behind the eye. In 2026, it is recognized as a breakthrough for preventing the disfiguring "bulging" and double vision associated with Graves' Orbitopathy.

read more about teprotumumab success rate ...

Copy this HTML:

Copy HTML Copied!

What Is the Overall Success Rate for Reducing Eye Bulging (Proptosis)?

Clinical data from 2026 indicates a remarkable 83 percent success rate for proptosis reduction. In pivotal trials, patients treated with teprotumumab achieved an average reduction of 3.3mm in eye bulging, with many patients returning to their pre-disease appearance. This is a significant improvement over standard steroids, which typically provide less than 1mm of proptosis reduction.

How Effective Is Teprotumumab at Resolving Double Vision (Diplopia)?

Double vision is one of the most debilitating symptoms of TED. Statistics show that 68 to 70 percent of patients experience an improvement of at least one "Gorman grade" in their diplopia after a full course of treatment. Approximately 53 percent of patients achieve complete resolution of double vision, potentially avoiding the need for complex strabismus surgery later in life.

What Is the Success Rate for Patients in the "Chronic" Phase of TED?

A major development in 2026 is the proven efficacy of teprotumumab in chronic, low-activity TED (disease duration of 2 to 10 years). Data from recent trials show that even in these long-standing cases, 62 percent of patients still achieve a significant reduction in proptosis (average 2.4mm). this has changed the clinical standard, as doctors no longer have to "wait out" the disease before offering medical intervention.

How Often Do Symptoms Recur After the Full Treatment Course?

The "durability" of teprotumumab is a key metric for long-term success. Follow-up data indicates that roughly 67 percent of patients maintain their proptosis and diplopia improvements for at least one year post-treatment. However, about 33 percent of patients may experience a "flare" or partial recurrence, particularly those who continue to smoke or have poorly controlled thyroid levels.

What Are the Most Common Side Effects and Discontinuation Rates?

While highly successful, teprotumumab has a distinct side-effect profile. Statistics reveal that muscle spasms occur in 25 percent of patients, and hearing-related issues (tinnitus or muffled hearing) are reported by 10 to 15 percent. In 2026, the treatment discontinuation rate is relatively low at 5 percent, as most side effects are managed through dose adjustments or resolve after the 8-infusion course is complete.

FAQs on Teprotumumab

How is the treatment administered?

Teprotumumab is given as an intravenous (IV) infusion once every three weeks for a total of eight doses. The entire treatment course takes approximately five months. In 2026, many patients receive these infusions at home through specialized nursing services or at dedicated infusion centers.

Does this medicine replace thyroid surgery?

Teprotumumab can often prevent the need for "Orbital Decompression" surgery, which is the procedure used to shave away bone to make room for bulging eyes. However, it does not replace the need for thyroid-regulating medications or radioactive iodine if your underlying thyroid hormone levels are still unstable.

Will my insurance cover this treatment?

Because it is a high-cost biological therapy, most insurance plans in 2026 require a "Prior Authorization" proving that your TED is moderate-to-severe (proptosis >3mm or significant double vision). Success rates for insurance approval have increased as long-term data proves it reduces the lifetime cost of multiple rehabilitative surgeries.

When to See Your Doctor

Consult an oculoplastic specialist if you notice your eyes appearing "staring" or bulging, or if you experience persistent pressure behind the eyes. Seek immediate care if you notice a sudden "graying" of colors or a drop in vision, as these are signs of "Compressive Optic Neuropathy," a rare emergency in TED where the swollen tissue squeezes the optic nerve.

References

  • Journal of Clinical Endocrinology & Metabolism. Efficacy of Teprotumumab in Chronic TED (academic.oup.com). 2025.
  • PMC. What Has Changed in Thyroid Eye Disease (2020?2025) (pmc.ncbi.nlm.nih.gov). 2026.
  • AAO. Teprotumumab Outcomes: Five-Year Longitudinal Data (aao.org). 2025.
  • Medicine Net. Tepezza Success and Side Effect Statistics (medicinenet.com). 2024.